Hyperpigmentation remains one of the most complex challenges in the global skincare industry. Many traditional brightening agents available on the market act aggressively on melanogenesis, causing skin irritation and triggering inflammatory processes that stimulate melanin production once again. This process, known as the rebound effect, limits both treatment efficacy and safety, especially for sensitive skin.
To overcome this limitation, Chemyunion introduces Peptid4® Light MB, a high-performance synthetic tetrapeptide designed to act directly on the biological mechanisms that originate dark spots, promoting progressive skin tone uniformity with enhanced safety and tolerability.
Facial hyperpigmentation is associated with excessive and uneven melanin production, often aggravated by subclinical inflammatory processes. In addition to being one of the most visible signs of skin aging, uneven skin tone impacts the perception of skin health and influences consumers’ relationship with their own image, driving demand for effective solutions compatible with sensitive skin.
A “Molecular Switch” for Intelligent Pigmentation Control
Peptid4® Light MB (INCI: Palmitoyl Tetrapeptide-112) was developed through in silico molecular design, targeting the melanocortin-1 receptor (MC1R), one of the key regulators of melanogenesis.
The ingredient acts as a high-affinity competitive antagonist of MC1R, modulating melanin production even before pigment formation occurs. By interrupting this signaling cascade, the active helps balance skin pigmentation while also controlling inflammatory mediators involved in the process.
This mechanism enables a smarter treatment approach by controlling pigmentation at its biological origin, preserving melanocyte integrity, promoting progressive tone uniformity, and reducing the risk of irritation in sensitive and reactive skin.
Proven Efficacy Through Multiple Studies
Studies conducted with Peptid4® Light MB demonstrated consistent results across biological markers related to hyperpigmentation and skin aging.
In an ex vivo study using human skin fragments incubated for 72 hours, the ingredient showed:
- 66% reduction in total melanin content compared to placebo.
Beyond pigmentation control, the active also demonstrated additional benefits for skin quality through firmness evaluation (immunofluorescence):
- 63% increase in type I collagen synthesis, contributing to improved skin firmness.
Efficacy was further confirmed through clinical evaluations using the VISIA-CR® imaging system under UV light, demonstrating progressive normalization of pigment distribution, with visible improvement from 28 days of use and continuous evolution over time.
To validate the ability of Peptid4® Light MB to break the inflammation–pigmentation cycle, an additional study monitored the Erythema Index (via Mexameter®), also confirming the peptide’s soothing effect on sensitive skin.
After 84 days of use, results showed:
- Significant improvement in skin radiance
- Reduction of melanin content in hyperpigmented areas
- Progressive skin tone uniformity
- Decrease in erythema index, indicating a soothing effect
Sustainability and Green Chemistry
Aligned with Clean Beauty demands, the ingredient contains 99.86% natural origin content (ISO 16128) and is developed under the principles of Green Chemistry.
Peptid4® Light MB is synthesized using Solid-Phase Peptide Synthesis (SPPS), optimized to ensure an exclusive process utilizing a PFAS-free production route, characterized by the absence of intentionally added per- and polyfluoroalkyl substances throughout synthesis and purification stages.
Key Market Differentiators
- Erythema control: reduces redness associated with hyperpigmented areas
- Firming action: helps smooth fine lines while improving tone uniformity
- Daytime compatibility: suitable for continuous use, including daytime, without the photosensitivity commonly associated with some depigmenting agents
- Sensitive skin compatibility: superior performance for sensitive and reactive skin
